Skip to content

Korsana Biosciences

US · KRSA #2830 by market cap Listed 1970
37.56 +2.11 +5.95%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Valuation each multiple against its own 5-year range

P/B ratio 3.68 In line with history 49th percentile
5-year average -4.58 · #342 of 514 in Biotechnology
P/E ratio -45.21 In line with history 51st percentile
5-year average -44.49 · forward -8.30
P/S ratio --
5-year average 0.00

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
Korsana Biosciences (KRSA) 1.71B -53.66 4.37 0.00%
Vertex Pharmaceuticals (VRTX) 130.58B 33.14 6.25 0.00%
Regeneron Pharmaceuticals (REGN) 95.24B 20.35 2.84 0.40%
Moderna (MRNA) 78.90B -27.70 11.54 0.00%
argenx SE (ARGX) 58.21B 32.06 6.92 0.00%
BeiGene (ONC) 44.66B 49.74 7.67 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value37.20 Economic moatNone UncertaintyVery High

Trading 1.0% above Morningstar's fair value estimate.

Fair value

Korsana Biosciences Inc is assigned a 3-star quantitative star rating, reflecting our opinion that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 15% discount to our quantitative fair value estimate of $37.20 per share; however, caution is warranted due to this estimate's very high uncertainty rating.

The firm's valuation metrics increase our fair value estimate. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. Reflecting the firm's valuation is its price to cash ratio of 3.1, which sits in the bottom 30% globally. Even if the company were to encounter financial distress, its cash balances could allow it to maneuver effectively. We believe this is a sign that shares could be cheap.

On a different note, the company's liquidity is potentially concerning. Low liquidity can inhibit a company from meeting short-term obligations, potentially reducing financial stability and increasing distress risk. The firm's median trading volume over the past 60 days, a core component of liquidity, falls in the bottom 45% globally. Relatively low trading volume for these shares could lead to prices that don't accurately reflect the intrinsic value of shares. Despite our favorable price/fair value ratio, this characteristic is a negative attribute.

Economic moat

With its quantitative economic moat rating of none, we do not expect this company to materially outearn its cost of capital in the long run.

By Quantitative Equity Report

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

Korsana Biosciences discussion 0 comments

Add a comment